Related references
Note: Only part of the references are listed.Incidence of liver- and non-liver-related outcomes in patients with HCV-cirrhosis after SVR
Roberta D'Ambrosio et al.
JOURNAL OF HEPATOLOGY (2022)
HCC risk stratification after cure of hepatitis C in patients with compensated advanced chronic liver disease
Georg Semmler et al.
JOURNAL OF HEPATOLOGY (2022)
Impact of liver-stiffness measurement on hepatocellular carcinoma development in chronic hepatitis C patients treated with direct-acting antivirals: A systematic review and time-to-event meta-analysis
Myung-Won You et al.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2021)
Hepatocellular carcinoma
Josep M. Llovet et al.
NATURE REVIEWS DISEASE PRIMERS (2021)
Clinical outcomes following DAA therapy in patients with HCV-related cirrhosis depend on disease severity
Lisette A. P. Krassenburg et al.
JOURNAL OF HEPATOLOGY (2021)
Long-Term Risk of Hepatocellular Carcinoma in HCV Patients Treated With Direct Acting Antiviral Agents
Fasiha Kanwal et al.
HEPATOLOGY (2020)
Non-invasive prediction of liver-related events in patients with HCV-associated compensated advanced chronic liver disease after oral antivirals
Monica Pons et al.
JOURNAL OF HEPATOLOGY (2020)
Personalized surveillance for hepatocellular carcinoma in cirrhosis - using machine learning adapted to HCV status
Etienne Audureau et al.
JOURNAL OF HEPATOLOGY (2020)
A Model Based on Noninvasive Markers Predicts Very Low Hepatocellular Carcinoma Risk After Viral Response in Hepatitis C Virus-Advanced Fibrosis
Sonia Alonso Lopez et al.
HEPATOLOGY (2020)
Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort study
Fabrice Carrat et al.
LANCET (2019)
Role of Liver Stiffness Measurement in Predicting HCC Occurrence in Direct-Acting Antivirals Setting: A Real-Life Experience
Luca Rinaldi et al.
DIGESTIVE DISEASES AND SCIENCES (2019)
Increased Risk for Hepatocellular Carcinoma Persists Up to 10 Years After HCV Eradication in Patients With Baseline Cirrhosis or High FIB-4 Scores
George N. Ioannou et al.
GASTROENTEROLOGY (2019)
Incidence and risk factors of early HCC occurrence in HCV patients treated with direct acting antivirals: a prospective multicentre study
Luca Rinaldi et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2019)
Factors Associated With Increased Risk of De Novo or Recurrent Hepatocellular Carcinoma in Patients With Cirrhosis Treated With Direct-Acting Antivirals for HCV Infection
Elisabetta Degasperi et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2019)
What Are the Benefits of a Sustained Virologic Response to Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection?
George N. Ioannou et al.
GASTROENTEROLOGY (2019)
Hepatocellular carcinoma risk assessment by the measurement of liver stiffness variations in HCV cirrhotics treated with direct acting antivirals
Federico Ravaioli et al.
DIGESTIVE AND LIVER DISEASE (2018)
Incidence of Hepatocellular Carcinoma After Direct Antiviral Therapy for HCV in Patients With Cirrhosis Included in Surveillance Programs
Pierre Nahon et al.
GASTROENTEROLOGY (2018)
Incidence of Hepatocellular Carcinoma in Patients With HCV-Associated Cirrhosis Treated With Direct-Acting Antiviral Agents
Vincenza Calvaruso et al.
GASTROENTEROLOGY (2018)
Newly diagnosed hepatocellular carcinoma in patients with advanced hepatitis C treated with DAAs: A prospective population study
Antonietta Romano et al.
JOURNAL OF HEPATOLOGY (2018)
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
Peter R. Galle et al.
JOURNAL OF HEPATOLOGY (2018)
Development of models estimating the risk of hepatocellular carcinoma after antiviral treatment for hepatitis C
George N. Ioannou et al.
JOURNAL OF HEPATOLOGY (2018)
Risk of cirrhosis-related complications in patients with advanced fibrosis following hepatitis C virus eradication
Adriaan J. van der Meer et al.
JOURNAL OF HEPATOLOGY (2017)
Hepatocellular carcinoma risk following direct-acting antiviral HCV therapy: A systematic review, meta-analyses, and meta-regression
Reem Waziry et al.
JOURNAL OF HEPATOLOGY (2017)
Diabetes and Cirrhosis Are Risk Factors for Hepatocellular Carcinoma After Successful Treatment of Chronic Hepatitis C
Magnus Hedenstierna et al.
CLINICAL INFECTIOUS DISEASES (2016)
Lack of evidence of an effect of direct-acting antivirals on the recurrence of hepatocellular carcinoma: Data from three ANRS cohorts
JOURNAL OF HEPATOLOGY (2016)
PITER: An ongoing nationwide study on the real-life impact of direct acting antiviral based treatment for chronic hepatitis C in Italy
Loreta A. Kondili et al.
DIGESTIVE AND LIVER DISEASE (2015)
Prospective comparison of transient elastography, fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C
L Castéra et al.
GASTROENTEROLOGY (2005)